BACKGROUND Brain cavernous angiomas with symptomatic hemorrhage (CASH) are
uncommon but exact a heavy burden of neurological disability from recurrent bleeding, for
which there is no proven therapy. Candidate drugs to stabilize the CASH lesion and prevent
rebleeding will ultimately require testing of safety and efficacy in multisite clinical trials. Much
progress has been made in understanding the epidemiology of CASH, and novel
biomarkers have been linked to the biological mechanisms and clinical activity in lesions …